The FDA says that food companies will have until Jan. 15, 2027 to stop using the dye. Drugmakers will have an extra year, ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.

Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, ...

Can this diabetes-control breakthrough also become the answer to obesity? From Hollywood’s red carpets to affluent Indians, ...

This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been ...

In the broader context, Eli Lilly’s Retatrutide shows stronger peak weight loss efficacy, with results nearing 25–30%, surpassing both CagriSema and Zepbound. While Retatrutide demonstrates a steeper ...

Although CagriSema's pivotal trial results were impressive, they pale in comparison to retatrutide, a triplet therapy Eli Lilly is testing. Retatrutide is a GLP-1/GIP agonist that also acts on ...

Its approval in this new indication should help increase the medicine's strong performance, and it's pursuing several other label expansions. Eli Lilly can also count on many years of sales growth ...